

Mei Qiu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6576/publications.pdf>

Version: 2024-02-01

36
papers

233
citations

1162889

8
h-index

1125617

13
g-index

39
all docs

39
docs citations

39
times ranked

191
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412110110.	0.9	41
2	Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. <i>Endocrine</i> , 2021, 73, 31-36.	1.1	19
3	Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data. <i>Osteoporosis International</i> , 2020, 31, 961-971.	1.3	15
4	SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort studies. <i>Pharmacological Research</i> , 2020, 161, 105175.	3.1	14
5	Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes. <i>Medicine (United States)</i> , 2021, 100, e23489.	0.4	7
6	GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression. <i>Diabetes Therapy</i> , 2020, 11, 2429-2440.	1.2	13
7	Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 34-37.	0.8	11
8	Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials. <i>Frontiers in Pharmacology</i> , 2021, 12, 724405.	1.6	10
9	Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 690529.	1.1	9
10	Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials. <i>Endocrine Journal</i> , 2021, 68, 739-742.	0.7	9
11	Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region. <i>Medicine (United States)</i> , 2020, 99, e23489.	0.4	7
12	Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107803.	1.2	7
13	Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs. <i>American Journal of Cardiovascular Drugs</i> , 2021, , 1.	1.0	7
14	Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases. <i>Medicine (United States)</i> , 2021, 100, e27362.	0.4	7
15	Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials. <i>Frontiers in Endocrinology</i> , 2021, 12, 743807.	1.5	7
16	Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis. <i>Endocrine</i> , 2020, 69, 688-691.	1.1	6
17	Network meta-analysis on the efficacy and safety of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis. <i>International Journal of Dermatology</i> , 2022, 61, e24-e26.	0.5	6
18	Does Combination Therapy With SGLT2 Inhibitors and Renin-Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events Among Patients With Type 2 Diabetes?. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 679124.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Do all gliflozins reduce stroke in patients with type 2 diabetes mellitus and impaired renal function?. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105799.	0.7	4
20	Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. <i>Frontiers in Pharmacology</i> , 2021, 12, 751496.	1.6	4
21	Impact of time factor and patient characteristics on the efficacy of PCI vs CABG for left main coronary disease. <i>Medicine (United States)</i> , 2021, 100, e25057.	0.4	3
22	Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?. <i>European Journal of Internal Medicine</i> , 2021, 87, 98-99.	1.0	3
23	Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 1077-1078.	1.3	3
24	Meta-analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF. <i>ESC Heart Failure</i> , 2021, 8, 1722-1724.	1.4	2
25	Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Endocrinology</i> , 2021, 12, 664502.	1.5	2
26	Comment on "SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies". <i>Pharmacological Research</i> , 2021, 172, 105862.	3.1	2
27	Double antithrombotic therapy for prevention of bleeding and ischemic events after percutaneous coronary intervention in patients with atrial fibrillation. <i>Medicine (United States)</i> , 2021, 100, e24188.	0.4	1
28	Letter Regarding "Systematic Review of Cardiovascular Outcome Trials Using New Antidiabetic Agents in CKD Stratified by Estimated GFR". <i>Kidney International Reports</i> , 2021, 6, 2934-2935.	0.4	1
29	Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials. <i>European Journal of Preventive Cardiology</i> , 2021, , .	0.8	1
30	Effects of SGLT2 inhibitors on cardiovascular death and all-cause death in patients with type 2 diabetes and chronic kidney disease: an updated meta-analysis including the SCORED trial. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2021, 12, 204201882110449.	1.4	0
31	Letter to the Editor regarding the article "SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis". <i>Heart Failure Reviews</i> , 2021, , 1.	1.7	0
32	SGLT2 inhibitors should be recommended in patients with one or more of the three diseases: type 2 diabetes, chronic kidney disease, and HFrEF. <i>European Journal of Internal Medicine</i> , 2021, 87, 102-103.	1.0	0
33	Cardiorenal benefits of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 575-577.	2.2	0
34	Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes. <i>European Journal of Clinical Pharmacology</i> , 2021, , 1.	0.8	0
35	Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. <i>Annals of Internal Medicine</i> , 2022, 175, W3-W4.	2.0	0
36	Is SGLT2i superior to DPP4i for primary and secondary prevention of cardiovascular diseases and death in patients with type 2 diabetes?. <i>Pharmacological Research</i> , 2021, 174, 105878.	3.1	0